Embed Size (px)
Citation preview
Quando associar platina ao tratamento do CRPC
(não neuroendócrino)
Denis F. Jardim, MD, PhDOncologista Titular Hospital Sírio Libanês-SP
Satraplatin
Quigley DA et al Cell 2018
TAXANES
AR abnormalities are not a negative predictive factor!
Quigley DA et al Cell 2018Conteduca V et al. Eur Urol 2019
Quigley DA et al Cell 2018Conteduca V et al. Eur Urol 2019
TAXANES
AR abnormalities are not a negative predictive factor!
Immuno Platinum
+ RB1 (Neuroendocrine-like)
DNA damage
Aggarwal et al. JCO 2018
• Up to 1/5 of mCRPC presents treatment-emergent SCNC • Shortened survival • Mutually exclusive with DNA repair alterations
DNA repair defects: therapeutic implications
16/18 (88%) responses olaparibe
Mateo J et al. NEJM 2015Pomerantz et al. Cancer 2017
6/8 (75%) responses carboplatinGermline BRCA2
Elevated Gleason combined with low PSA are associated with a Neuroendocrine signatureMahal BA et al. Eur Urol 2018
Aparicio A et al. CCR 2013
Phase IImCRPCAgressive VariantN=135
Cabazitaxel
Cabazitaxel+
Carboplatin
Corn PG et al. ASCO 2015
